Health Information Technology System ("Roadmap 2.0") in the Context of Hematopoietic Cell Transplantation

  • End date
    Dec 31, 2023
  • participants needed
  • sponsor
    University of Michigan Rogel Cancer Center
Updated on 25 March 2022
cell transplantation


The purpose of this research study is to measure the effects of using a mobile phone app (Roadmap 2.0) on the health-related quality of life of caregivers and patients undergoing allogeneic/autologous hematopoietic cell transplantation (HCT).


Health information technology tools may enable caregivers and patients to become more active participants in their healthcare.This study is not to provide any treatment, but rather to investigate the use of this mobile health technology-mediated intervention (Roadmap 2.0). Roadmap 2.0 is a web-based application that integrates patient-specific information and includes several domains: laboratory results, medications, clinical trial details, photos of the healthcare team, trajectory of transplant process, and discharge checklist.

This trial is anticipated to enroll 664 participants, but only caregivers (332 total) will be evaluated for the primary and secondary outcome measures. Thus, the sample size is 332. The total enrollment includes 166 caregiver-patient dyads of adult patients (age >/=18 years) undergoing HCT ("adult dyads" = 332 total) and 166 caregiver-patient dyads of pediatric patients (age 5-17 years) undergoing HCT ("pediatric dyads" = 332 total).

Condition Hematologic Diseases
Treatment survey administration, Wearable activity sensor, Roadmap 2.0 information system, Roadmap 2.0 information system with Positive Activities
Clinical Study IdentifierNCT04094844
SponsorUniversity of Michigan Rogel Cancer Center
Last Modified on25 March 2022


Yes No Not Sure

Inclusion Criteria

The caregiver must have an eligible patient (see below)
The caregiver must be of age ≥18 years
The caregiver should be comfortable in reading and speaking English and signing informed consents
The caregiver should provide at least 50% of care needs
An eligible patient is one who identifies the eligible caregiver as their primary caregiver (i.e., provides at least 50% of care needs)
An eligible patient is age ≥5 years
An eligible patient is scheduled to undergo HCT
An eligible patient is able to sign informed consent/assent forms
Patients and caregivers agree to provide informed consent that is in regulatory compliance and IRBMED-approved and also in accordance to institutional guidelines. A patient is able to undergo HCT at the U-M only if a designated family caregiver (e.g., parents, adult children, spouses, family members, neighbors, friends) accepts the roles, in accordance to the Clinical Practice Guidelines of the U-M BMT Program
The caregiver and patient must have his/her own smartphone to participate

Exclusion Criteria

Patient does not meet eligibility criteria to undergo HCT at the U-M BMT Program or Oregon Health & Sciences University
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note